In this guide
What is Stinging Nettle Root?
Stinging nettle root is different from nettle leaf. A small modern trial reported symptom improvement, while an older large study lacks a recoverable dose and independent replication remains limited. No U.S. RDA, AI, UL or established urinary regimen exists for nettle root. Product claims should preserve Urtica dioica, the root, the extraction and the exact schedule rather than generalizing from leaves or whole-herb products.
Typical Stinging Nettle Root Protocols
| Source and population | Form and amount each time | Frequency | Total exposure | Duration or boundary |
|---|---|---|---|---|
| Karami 2020 · 60 randomized; 56 analyzed | Urtidin root dry extract 150 mg per tablet | Three times daily | 450 mg/day | 12 weeks; IPSS improved |
| Safarinejad 2005 · 620 randomized; 558 completed | Urtica dioica preparation; exact dose and plant-part specification not recovered | Frequency not recovered | Daily total not recovered | 6 months blinded; partial crossover to 18 months |
| Melo 2002 · 49 participants | Nettle extract 300 mg plus pygeum extract 25 mg per tablet | One tablet twice daily | Nettle 600 mg + pygeum 50 mg/day | 6 months; no significant benefit |
These rows reproduce sources. Do not average them into one universal regimen.
From source to outcome
Do not merge products.
450 mg/day for 12 weeks.
Older dose unrecovered.
Which forms and label details matter?
Record root versus leaf, extract versus powder, Urtica species, amount each time and standardization. The 2020 Urtidin tablet contained 150 mg root dry extract and was described as standardized to 22 mg alanine per tablet.
How should it be stored?
Follow the label, close the container and protect it from heat, light and moisture.
Read the label before the claim
Keep species, part and extract together.
A daily total does not reveal the schedule.
Biomarkers do not replace clinical outcomes.
What is it commonly used for?
Root products are marketed for lower urinary tract symptoms and benign prostate enlargement. Leaf products are marketed for different uses; evidence from leaf or aerial parts should not be imported into a root guide.
What does human research show?
Karami randomized 60 men; 56 were analyzed after 12 weeks of 150 mg root extract three times daily or placebo. IPSS improved, while most other biochemical and clinical measures were negligible or nonsignificant; the study was small and requires replication. [1] Safarinejad randomized 620 men and reported favorable symptom, flow and residual-volume findings after six months, with 558 completers. The accessible primary record does not report dose or enough preparation identity, and the partial crossover/open extension complicates long-term interpretation. [2] Melo gave a pygeum 25 mg plus nettle 300 mg tablet twice daily to 27 participants and placebo to 22 for six months; symptoms, quality of life and flow did not differ significantly. [3]

How might it act?
Root lignans and sterols have been studied for binding and prostate-related pathways, while other constituents may affect inflammation. Mechanistic work does not make leaf and root preparations equivalent or establish symptom relief.
How does it compare with related products?
| Product | Identity to preserve | Evidence boundary |
|---|---|---|
| Saw palmetto | Species, berry extract and fatty-acid standardization | High-quality monotherapy trials are largely null |
| Pygeum | Prunus africana bark extract and extract specification | Older, short trials with weak reporting |
| Stinging nettle root | Root extract, not leaf or whole-herb products | A few trials; preparation identity often incomplete |
| Zinc | Elemental zinc and nutritional status | Nutrient context; deficiency correction is a separate question |
What are the risks and interactions?
Short trials reported few adverse events, but that is not proof of long-term safety. Review allergy to nettle, blood pressure or glucose medicines, diuretics, kidney disease, pregnancy, breastfeeding and planned surgery. Do not self-treat urinary retention or blood in urine. [4]
Which medicines require review?
Have the product reviewed with medicines, before surgery, and during pregnancy or breastfeeding. No universal separation interval is established.
Regulatory status: In the United States, supplements generally lack premarket efficacy approval. In Canada, verify the finished product’s NPN or DIN-HM and licensed conditions. [5], [6]
What should be monitored?
Record product, lot, form, amount per administration, frequency, daily total, co-ingredients, meals, symptoms, medicines, chosen outcome and review date.
What happens when it is stopped?
No ingredient-specific withdrawal syndrome is established. Record the stop date, symptoms and chosen outcome; seek care for a persistent serious symptom.
Seek prompt care for a serious allergic reaction, unusual bleeding, persistent palpitations, chest pain or another severe symptom.
What do public communities report?
Public reports can suggest questions to track, but they do not verify the product, dose or causality. This update did not newly quantify a community sample.
Common questions about Stinging Nettle Root
Is nettle root the same as nettle leaf?
No. Plant part and extraction differ, and evidence should not be transferred.
What exact schedule was used in the 2020 trial?
A 150 mg root-extract tablet three times daily, totaling 450 mg/day for 12 weeks.
Does the 620-person study establish a dose?
No. Its accessible primary record did not recover dose or adequate preparation details.
Did nettle plus pygeum work?
The small accessible combination trial found no significant advantage over placebo.
Can it replace BPH medicines?
No. Treatment choices depend on diagnosis, symptom severity, retention risk and medicine review.
What should I track?
Species, root preparation, amount each time, schedule, urinary symptoms, blood pressure, glucose and adverse effects.
Glossary
Terms for reading the evidence.
- Extract identity
- Species, plant part, solvent or ratio, and any standardization used to define a preparation.
- Amount per administration
- Amount taken at one time, distinct from daily total.
- IPSS / AUASI
- Questionnaires rating lower urinary tract symptom severity; they do not diagnose the cause.
- Qmax
- Maximum measured urinary flow rate.
- PSA
- A prostate-related blood marker; it is not a stand-alone cancer test.
- Monotherapy
- The ingredient was tested without another active intervention.
How this guide was researched
Accessible official sources and human reports were read on October 9, 2026. Titles, authors, journals, DOI, PMID and visible corrections were checked. An unreported frequency was not guessed.
How this guide was made
Research and drafting were AI-assisted. This draft awaits Doserly editorial review and independent clinical review. See the editorial policy.
Explore the sources
Sources preserve form, amount, frequency, population, duration and outcome.
Showing 6 sources
- 01
Urtica Dioica Root Extract on Clinical and Biochemical Parameters in Patients with Benign Prostatic Hyperplasia, Randomized Controlled Trial. ↗
Randomized root-extract trial
Current page or report reviewed; scope and limits retained.
Detail: 60 randomized; 450 mg/day for 12 weeks.
- 02
Urtica dioica for treatment of benign prostatic hyperplasia ↗
Randomized crossover trial
Current page or report reviewed; scope and limits retained.
Detail: Publisher record verified; 620 randomized; accessible record lacks dose and preparation detail.
- 03
Evaluating the efficiency of a combination of Pygeum africanum and stinging nettle (Urtica dioica) extracts in treating benign prostatic hyperplasia (BPH): double-blind, randomized, placebo controlled trial. ↗
Combination trial
Current page or report reviewed; scope and limits retained.
Detail: 49 participants; one 25 mg/300 mg tablet twice daily; no significant advantage.
- 04
Nettle ↗
Clinical herb monograph
Current page or report reviewed; scope and limits retained.
Detail: Preparation distinctions, adverse effects and interaction context.
- 05
Dietary Supplements ↗
Regulatory overview
Current page or report reviewed; scope and limits retained.
Detail: U.S. supplement framework.
- 06
About Natural Health Products ↗
Regulatory overview
Current page or report reviewed; scope and limits retained.
Detail: Canadian product licensing and NPN context.
No matching sources
Try a different term or show the full list.